[
  {
    "criterion": "Mentions microRNA biomarkers as a potential diagnostic tool for preclinical Alzheimer's disease.",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Provides a clear and concise explanation of the limitations of microRNA biomarkers in diagnosing preclinical Alzheimer's disease.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Fails to mention any relevant research or studies on the use of microRNA biomarkers in diagnosing preclinical Alzheimer's disease.",
    "axis": "completeness",
    "point": -8
  },
  {
    "criterion": "Does not address the user's role as a physician and fails to provide guidance on how to incorporate microRNA biomarkers into their practice.",
    "axis": "context_awareness",
    "point": -6
  },
  {
    "criterion": "Provides overly technical or complicated information about microRNA biomarkers, making it difficult for a physician to understand.",
    "axis": "communication_quality",
    "point": -5
  },
  {
    "criterion": "Mentions the potential for microRNA biomarkers to be used as a diagnostic tool for Alzheimer's disease, but fails to provide any evidence to support this claim.",
    "axis": "accuracy",
    "point": -7
  },
  {
    "criterion": "Provides a list of potential research directions for investigating the use of microRNA biomarkers in diagnosing preclinical Alzheimer's disease, but fails to provide any concrete recommendations for the user.",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Mentions the importance of considering multiple biomarkers in diagnosing preclinical Alzheimer's disease, but fails to provide any specific examples of these biomarkers.",
    "axis": "accuracy",
    "point": -2
  },
  {
    "criterion": "Provides a clear and concise explanation of the potential benefits and limitations of using microRNA biomarkers in diagnosing preclinical Alzheimer's disease, and provides specific examples of relevant research studies.",
    "axis": "communication_quality",
    "point": 9
  },
  {
    "criterion": "Fails to provide any information about the potential risks or side effects associated with using microRNA biomarkers in diagnosing preclinical Alzheimer's disease.",
    "axis": "completeness",
    "point": -9
  },
  {
    "criterion": "Mentions the potential for microRNA biomarkers to be used as a diagnostic tool for Alzheimer's disease, and provides specific examples of relevant research studies.",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Provides a clear and concise explanation of the importance of considering the user's role as a physician when using microRNA biomarkers in diagnosing preclinical Alzheimer's disease.",
    "axis": "context_awareness",
    "point": 7
  },
  {
    "criterion": "Fails to provide any information about the potential impact of microRNA biomarkers on the diagnosis and treatment of Alzheimer's disease.",
    "axis": "completeness",
    "point": -7
  },
  {
    "criterion": "Mentions the potential for microRNA biomarkers to be used as a diagnostic tool for Alzheimer's disease, and provides a clear and concise explanation of the potential benefits and limitations of this approach.",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Provides a clear and concise explanation of the potential risks and benefits associated with using microRNA biomarkers in diagnosing preclinical Alzheimer's disease, and provides specific examples of relevant research studies.",
    "axis": "communication_quality",
    "point": 10
  }
]